World malaria report 2023 World Health Organization World Health Organization, 2023 | 14662* | 2023 |
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study L Beaugerie, N Brousse, AM Bouvier, JF Colombel, M Lémann, J Cosnes, ... The Lancet 374 (9701), 1617-1625, 2009 | 1233 | 2009 |
Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection O Hermine, F Lefrère, JP Bronowicki, X Mariette, K Jondeau, ... New England Journal of Medicine 347 (2), 89-94, 2002 | 981 | 2002 |
Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria P Valent, C Akin, L Escribano, M Födinger, K Hartmann, K Brockow, ... European journal of clinical investigation 37 (6), 435-453, 2007 | 903 | 2007 |
Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial O Hermine, X Mariette, PL Tharaux, M Resche-Rigon, R Porcher, ... JAMA internal medicine 181 (1), 32-40, 2021 | 900 | 2021 |
Gene therapy in patients with transfusion-dependent β-thalassemia AA Thompson, MC Walters, J Kwiatkowski, JEJ Rasko, JA Ribeil, ... New England Journal of Medicine 378 (16), 1479-1493, 2018 | 717 | 2018 |
Transforming growth factor β1, in the presence of granulocyte/macrophage colony-stimulating factor and interleukin 4, induces differentiation of human peripheral blood … F Geissmann, C Prost, JP Monnet, M Dy, N Brousse, O Hermine The Journal of experimental medicine 187 (6), 961-966, 1998 | 645 | 1998 |
Treatment of older patients with mantle-cell lymphoma HC Kluin-Nelemans, E Hoster, O Hermine, J Walewski, M Trneny, ... New England Journal of Medicine 367 (6), 520-531, 2012 | 637 | 2012 |
Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA) O Hermine, C Haioun, E Lepage, MF d'Agay, J Briere, C Lavignac, G Fillet, ... | 614 | 1996 |
Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting K Tsukasaki, O Hermine, A Bazarbachi, L Ratner, JC Ramos, ... Journal of Clinical Oncology 27 (3), 453-459, 2009 | 598 | 2009 |
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis A Jaccard, P Moreau, V Leblond, X Leleu, L Benboubker, O Hermine, ... New England Journal of Medicine 357 (11), 1083-1093, 2007 | 589 | 2007 |
Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation F Suarez, O Lortholary, O Hermine, M Lecuit Blood 107 (8), 3034-3044, 2006 | 554 | 2006 |
Caspase activation is required for terminal erythroid differentiation Y Zermati, C Garrido, S Amsellem, S Fishelson, D Bouscary, F Valensi, ... The Journal of experimental medicine 193 (2), 247-254, 2001 | 517 | 2001 |
TGF-β1 prevents the noncognate maturation of human dendritic Langerhans cells F Geissmann, P Revy, A Regnault, Y Lepelletier, M Dy, N Brousse, ... The Journal of Immunology 162 (8), 4567-4575, 1999 | 517 | 1999 |
Efficacy and safety of midostaurin in advanced systemic mastocytosis J Gotlib, HC Kluin-Nelemans, TI George, C Akin, K Sotlar, O Hermine, ... New England Journal of Medicine 374 (26), 2530-2541, 2016 | 501 | 2016 |
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study S Choquet, V Leblond, R Herbrecht, G Socié, AM Stoppa, ... Blood 107 (8), 3053-3057, 2006 | 499 | 2006 |
Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis P Domingo, I Mur, GM Mateo, M del Mar Gutierrez, V Pomar, N de Benito, ... Jama 326 (6), 499-518, 2021 | 486 | 2021 |
CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans S Weller, A Faili, C Garcia, MC Braun, F Le Deist, G de Saint Basile, ... Proceedings of the National Academy of Sciences 98 (3), 1166-1170, 2001 | 475 | 2001 |
Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, J Manry, ... Science immunology 6 (62), eabl4340, 2021 | 473 | 2021 |
ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment? D Petrov, C Mansfield, A Moussy, O Hermine Frontiers in aging neuroscience 9, 68, 2017 | 471 | 2017 |